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Inflammatory Markers Associated With Subclinical Coronary Artery
Disease: The Multicenter AIDS Cohort Study
Hossein Bahrami,MD, PhD,MPH;MatthewBudoff,MD; SabinaA. Haberlen, PhD; Pantea Rezaeian,MD; KerunneKetlogetswe,MD,MS; Russell
Tracy, PhD; Frank Palella, MD; Mallory D. Witt, MD; Michael V. McConnell, MD, MSEE; Lawrence Kingsley, PhD; Wendy S. Post, MD, MS
Background-—Despite evidence for higher risk of coronary artery disease among HIV+ individuals, the underlying mechanisms are
not well understood. We investigated associations of inflammatory markers with subclinical coronary artery disease in 923
participants of the Multicenter AIDS Cohort Study (575 HIV+ and 348 HIV men) who underwent noncontrast computed
tomography scans for coronary artery calcification, the majority (n=692) also undergoing coronary computed tomography
angiography.
Methods and Results-—Outcomes included presence and extent of coronary artery calcification, plus computed tomography
angiography analysis of presence, composition, and extent of coronary plaques and severity of coronary stenosis. HIV+ men had
significantly higher levels of interleukin-6 (IL-6), intercellular adhesion molecule-1, C-reactive protein, and soluble-tumor necrosis
factor-a receptor (sTNFaR) I and II (all P<0.01) and a higher prevalence of noncalcified plaque (63% versus 54%, P=0.02) on
computed tomography angiography. Among HIV+ men, for every SD increase in log-interleukin-6 and log intercellular adhesion
molecule-1, there was a 30% and 60% increase, respectively, in the prevalence of coronary stenosis ≥50% (all P<0.05). Similarly,
sTNFaR I and II in HIV+ participants were associated with an increase in prevalence of coronary stenosis ≥70% (P<0.05). Higher
levels of interleukin-6, sTNFaR I, and sTNFaR II were also associated with greater coronary artery calcification score in HIV+ men
(P<0.01).
Conclusions-—Higher inflammatory marker levels are associated with greater prevalence of coronary stenosis in HIV+ men. Our
findings underscore the need for further study to elucidate the relationships of inflammatory pathways with coronary artery disease
in HIV+ individuals. ( J Am Heart Assoc. 2016;5:e003371 doi: 10.1161/JAHA.116.003371)
Key Words: atherosclerosis • cardiac biomarkers • cardiac computed tomography • coronary artery calcium • coronary artery
disease • coronary computed tomography scan • epidemiology • HIV • HIV infection • inflammation
H IV infection continues to be a major public healthproblem, affecting 34 million people worldwide.1 Suc-
cessful control of viremia with antiretroviral therapy (ART) has
changed the portrait of the infection from a fatal disease to a
chronic medical condition. Therefore, other diseases such as
cardiovascular diseases (CVD) increasingly become a major
health concern for these patients.2–8 Studies have found
higher rates of cardiovascular abnormalities, including coro-
nary artery disease (CAD), in HIV patients.5,9–15 It is estimated
that HIV-infected (HIV+) individuals are at 1.5- to 2-fold higher
risk of CAD compared to individuals without HIV (HIV).2,16
Despite the increasing evidence for the higher risk of CAD
in HIV+ individuals, the mechanisms involved in this increased
risk are not well understood. The initial research focused on
higher prevalence of traditional risk factors in HIV patients17–
19 and on ART.20–24 However, more recent studies suggest
that HIV-related inflammation plays a central role in this
increased risk.25–27 While the initiation of ART reduces
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inflammation, even virologically suppressed HIV+ patients
have higher levels of inflammation than individuals without
HIV,28,29 which may play a role in increased risk of CVD. This
is particularly important in view of the complex mixture of
immune activation and immune depletion in HIV infection and
our increasing knowledge of the role of inflammation in CVD
in the general population.30–33
One of the challenges in studying the mechanisms involved
in increased risk of CAD among HIV-infected patients is the
large number of subjects required, even in the high-risk
populations, with CAD clinical events as the outcome(s).
Therefore, detecting subclinical CAD has become a new focus
of research in this field, since subclinical atherosclerosis is a
common surrogate related to the risk of clinical events.34
Coronary artery calcification (CAC) detected by noncontrast
cardiac computed tomography (CT) is generally used as a
proxy measure of subclinical CAD. Although it has been
shown that HIV+ individuals are at increased risk of subclin-
ical atherosclerosis in the carotid artery,9,12,35,36 studies
using CAC as a measure of subclinical CAD have been
inconclusive.37–39 Contrast-enhanced coronary CT angiogra-
phy (CTA) provides a more detailed evaluation of subclinical
CAD, by imaging noncalcified plaques; and with advances in
technology, it can be done with a low radiation exposure.40
CTA provides a more comprehensive assessment of coronary
atherosclerosis, including plaque characterization and degree
of stenosis, thus identifying lesions that are known to be
associated with the risk of clinical CAD events.41,42 In a
systematic review of 32 studies, the odds of cardiac death
and myocardial infarction among those with coronary stenosis
(≥50%) is about 15 times of those with nonobstructive (<50%)
stenosis.43
We previously reported the relationships of biomarkers of
monocyte activation44 with subclinical CAD, using noncon-
trast CT scans and CTA studies, in HIV+ and HIV partici-
pants of the Multicenter AIDS Cohort Study (MACS). The
objective of the current study is to determine the association
of a suite of biomarkers of systemic inflammation and
coagulation with subclinical CAD in HIV+ and HIV partici-
pants in MACS. The study tests the hypothesis that biomark-
ers of inflammation and coagulation are higher in HIV+
patients and are correlated with subclinical CAD detected on
CT scan.
Methods
Population
The study population consisted of HIV+ and HIV men
enrolled in the MACS who underwent noncontrast CT scans,
as part of a MACS Cardiovascular Ancillary Study. Detailed
description of MACS and the subset of the participants who
had cardiac CT scans has been reported previously.45,46
Briefly, MACS is an ongoing cohort study of the natural and
treated histories of HIV-1 infection in homosexual and
bisexual men, conducted in 4 US communities in Baltimore,
Chicago, Pittsburgh, and Los Angeles. The study had an initial
enrollment in 1984–1985, with additional enrollments in
1987–1991 and 2001–2003. The cohort has recruited both
HIV+ and HIV men who attend semiannual research visits
during which they undergo standardized interviews and
physical examinations, and blood and urine samples are
collected.
Inclusion criteria for this MACS Cardiovascular Ancillary
Study were the following: being an active MACS participant
(with oversampling of HIV-infected men), age 40 to 70 years,
weight <300 lb, and no prior history of cardiac surgery or
percutaneous coronary intervention, as these procedures
would interfere with the measurement of coronary atheroscle-
rosis. Exclusion criteria for CTA measurements included the
following: atrial fibrillation, chronic kidney disease (estimated
glomerular filtration rate <60 mL/min per m2 within 30 days
of the CT scan) or a history of intravenous contrast allergy.
The study was approved by the Institutional Review Boards of
all participating sites, and all participants signed informed
consent for the MACS Cardiovascular Ancillary Study. All
eligible participants who were enrolled completed noncon-
trast cardiac CT scanning between January 2010 and June
2013. A total of 1005 (620 HIV+ and 385 HIV) men
underwent noncontrast coronary CT scans. From these
participants, 764 (453 HIV+ and 311 HIV) participants
underwent CTA.
Outcomes
The main outcomes of this study were measures of subclinical
CAD as measured by cardiac CT scans. These include
presence and also the extent of CAC measured on noncon-
trast CT scan and characteristics of coronary plaques and the
presence and severity of coronary artery stenosis measured
by CTA. Specific outcomes of interest were as follows:
moderate to severe coronary artery stenosis (≥50%), severe
coronary artery stenosis (≥70%), presence of CAC, Agatston
CAC score, presence of any plaque on CTA, calcified plaque
score, noncalcified plaque score, mixed plaque score, and
total plaque score on CTA.
CT Scan Studies
Details of the CT scan studies and procedures have been
described previously.46,47 Briefly, participants received b-
blocker or calcium channel blocker medications as needed in
anticipation of the CT scan study, and sublingual nitroglycerin
was administered prior to intravenous contrast injection
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unless contraindicated. CT scanning equipment included 64-
slice multidetector CT at 3 centers and a 320-row multide-
tector CT scanner in 1 center. Prospective ECG triggering
protocols, which minimized radiation exposure, were used,
except when the heart rate was too fast or irregular. The
median (interquartile range) radiation dose for the CTA
procedure was 1.9 (1.7–2.7) mSv. CT images were transferred
to the core CT reading center (Biomedical Research Institute
at Harbor-UCLA, Los Angeles, CA) and were analyzed and
interpreted by trained, experienced readers who were blinded
to participant characteristics and HIV serological status.
Segments were analyzed using a modified 15-segment model
of the American Heart Association.48 Using axial images,
multiplanar reconstructions, and maximum intensity projec-
tions, the presence, size, and composition of coronary plaque
and the degree of luminal narrowing (ie, stenosis) in all
assessable coronary segments were assessed. Plaque sizes
were graded as 0=no plaque, 1=mild, 2=moderate, or
3=severe. Segment stenosis was defined as 0=no plaque,
1=1% to 29% (minimal) stenosis, 2=30% to 49% (mild)
stenosis, 3=50% to 69% (moderate) stenosis, or 4 for ≥70%
(severe) stenosis. Moderate to severe stenosis (≥50%)
included lesions with grade 3 or 4. The total plaque score, a
reproducible measure of overall plaque burden,49 was calcu-
lated by summing the plaque size score for all assessable
coronary segments that demonstrated any plaque (calcified,
noncalcified, or mixed) up to a maximum score of 45. Each
coronary segment was classified as normal or containing
noncalcified plaque, mixed plaque (<50% of plaque area
occupied by calcium), or calcified plaque. Calcified atheroscle-
rotic plaque was defined as any structure with attenuation
>130 HU visualized separately from the intravascular lumen,
identified in at least 2 independent planes. Noncalcified
atherosclerotic plaque was defined as any discernible struc-
ture that could be clearly assignable to the vessel wall, with a
CT density less than the contrast-enhanced coronary lumen
but greater than the surrounding connective tissue, and
identified in at least 2 independent planes. The noncalcified
plaque score, mixed plaque score, and calcified plaque score
were calculated by summing the plaque scores in each
noncalcified, mixed, or calcified plaque segment separately.
Exposures and Covariables
The main independent variables of interest in this study were
inflammatory and coagulation biomarkers, which were mea-
sured on the day of the CT scan. The biomarkers included in
this study, and the domains they represent, were as follows:
interleukin-6 (IL-6; systemic inflammation), intracellular adhe-
sion molecule 1 (ICAM-1; endothelial cell activation), fibrino-
gen, and high sensitivity C-reactive protein (hs-CRP; both
acute phase response liver proteins), D-dimer (activation of
the coagulation and fibrinolytic systems), and soluble tumor
necrosis factor-a (TNF-a) receptor I (sTNFaR I), and soluble
TNF-a receptor II (sTNFaR II; TNF-mediated immune cell
activation). IL-6 (serum) was measured using chemilumines-
cent ELISA (R&D Systems, Minneapolis, MN). ICAM-1 (serum)
was also measured using R&D ELISA. Fibrinogen (EDTA
plasma) and hs-CRP (serum) were measured using the BNII
Nephelometer Siemens (Siemens Healthcare Diagnostics,
Deerfield, IL) and D-dimer (citrated plasma) was measured
using a Stago (Parsippany, NJ) STA-R analyzer. sTNFaR I and
sTNFaR II (EDTA plasma) were measured via multiplexing
using a Milliplex soluble cytokine receptor panel (Millipore,
Billerica, MA). The interassay coefficients of variation ranged
from 7% to 12% for IL-6, 3.3% to 7% for ICAM-1, 1.0% to 6.7%
for fibrinogen, 4% to 17% for D-dimer, 4.5% to 5.2% for hsCRP,
4.6% to 10.8% for sTNFaR I, and 4.2% to 7.9% for sTNFaR II.
Other variables measured and included in the analysis
included demographic data, traditional CAD risk factors, and
clinical parameters pertaining to HIV infection. MACS partic-
ipants are seen every 6 months as part of their routine visit,
and the data collected in the prior MACS study visit closest to
the CT scan were used for this study. Demographic and
cohort-related variables included in the analysis were age,
self-reported race/ethnicity, study center, and study cohort
(pre- versus post-2001). The traditional CAD risk factors
included systolic blood pressure, antihypertensive medication
use, diabetes medication use, fasting glucose, total choles-
terol, HDL cholesterol, use of lipid-lowering medications, body
mass index, smoking, and pack-years of smoking. Serum
glucose, total and high-density lipoprotein cholesterol (HDL),
and triglycerides were measured from fasting blood samples.
Low-density lipoprotein cholesterol was calculated using the
Friedewald equation or measured directly in persons with
triglycerides >400 mg/dL or with nonfasting samples. Serum
creatinine was measured at each MACS study visit and within
30 days of CT scanning for persons who underwent contrast
injection. Estimated glomerular filtration rate was calculated
using the Modification of Diet in Renal Disease equation.
Hypertension was defined as systolic blood pressure
>140 mm Hg or diastolic blood pressure >90 mm Hg or
self-reported use of antihypertensive medication. Diabetes
mellitus was defined as fasting serum glucose ≥126 mg/dL
or use of medications to treat diabetes. The clinical param-
eters of HIV infection included HIV duration, current viral load,
current and nadir CD4+ T-cell counts, and history of an AIDS-
defining malignancy or opportunistic infection, and duration of
highly active ART use.
Statistical Analysis
The distributions of continuous variables were summarized
using mean (SD) for continuous variables with normal
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distribution, median (interquartile range) for continuous
variables with non-Gaussian distribution, and percentage for
categorical variables. The comparisons between HIV-infected
and -uninfected participants were done using Student t test,
Wilcoxon rank-sum test, and v2 test. Poisson regression
models with robust variance50 (for binary outcomes) and
linear regression models (for continuous outcomes) were used
for analyzing the relationship of the inflammatory biomarkers
with the outcomes of interest detailed above (measures of
subclinical atherosclerosis and plaque characterizations). The
variables that did not have normal distribution were log
transformed or categorized. The analyses included 3 models:
(1) Model 1: minimally adjusted models included age, race/
ethnicity (white, African American, and Hispanic/Others),
study center, and study cohort (pre- versus post-2001);
(2) Model 2: minimally adjusted models plus traditional CAD
risk factors (systolic blood pressure, antihypertensive medi-
cation use, diabetes medication use, fasting glucose, total
cholesterol, HDL cholesterol, use of lipid-lowering medica-
tions, body mass index, smoking [current, former, never], and
pack-years of smoking); and (3) Model 3: (in HIV-infected
participants): Model 2 plus clinical parameters of HIV infection
(HIV duration, current viral load, current and nadir CD4+ T-cell
counts, and history of an AIDS-defining malignancy or
opportunistic infection, and duration of ART use). In order to
facilitate the comparison among different inflammatory
biomarkers, they were standardized using their SD. Therefore,
the prevalence ratios in Poisson models and the coefficients
in the linear regression models are per SD increase in the
level of inflammatory biomarkers. Also, in order to allow for
comparison among inflammatory biomarkers, the regression
analyses were limited to those participants in whom none of
the primary inflammatory biomarkers were missing. The
prevalence of missing values for CAD risk factors and clinical
parameters of HIV infection were negligible (less than 3%) in
these participants. Sensitivity analyses were also done by
imputing the missing values for biomarkers and risk factors
using multiple imputations. In addition to the models above, we
test for effect modification in Models 1 and 2 with all the men
(HIV+ and HIV) and included HIV serostatus and the
interaction terms between HIV serostatus and inflammatory
biomarkers. All statistical analyses were performed using Stata
10.1 (StataCorp Lp, College Station, TX). Statistical significance
was generally considered at a P value of 0.05 or less.
Results
The study population included 923 (575 HIV-infected (HIV+]
and 348 uninfected [HIV] men) MACS participants who
underwent noncontrast CT scans, including 692 who under-
went CTA, and had inflammatory biomarkers measured. As
described in the Methods section, from 1005 participants
who had noncontrast CT scans, 82 men were excluded in the
main analysis due to missing values for at least 1 inflamma-
tory biomarker. The distribution of risk factors among these
excluded participants were similar to the 923 participants
included in this study, with the exception of serum HDL values
(mean: 46 versus 51, respectively, P=0.02). Otherwise,
Table 1 summarizes the baseline characteristics of the study
population. HIV+ men were on average 2.7 years younger
than uninfected individuals and were less likely to be white,
had a 4 pack-year higher average smoking history, lower body
mass index, lower serum low-density lipoprotein cholesterol
and HDL cholesterol levels, and higher triglyceride levels.
Most of the HIV+ participants (96%) had been on ART at some
point and the majority of them (83%) were virologically
suppressed with average current CD4+ T-cell count of
703 cells/mm3 (Table 1).
HIV+ men had significantly higher blood levels of IL-6,
ICAM-1, hs-CRP, sTNFaR I, and sTNFaR II compared to HIV
men (all P<0.01), while there was no statistically significant
difference in the serum levels of the coagulation marker
D-dimer between the 2 groups (Table 2). Limiting HIV+ men
to those with undetectable viral load did not significantly
change these results (Table 3).
Detailed analyses of the relationships between selected
CAD risk factors and HIV clinical factors with the biomarkers
of inflammation and coagulation is beyond the scope of this
article. However, a few of the associations are worth
mentioning here. Among CAD risk factors, increased age
was a consistent predictor of all the studied biomarkers,
except hs-CRP, both in HIV+ and HIV men. Black race was
associated with higher levels of IL-6 and fibrinogen in both
HIV+ and HIV men, higher levels of D-dimer in HIV men,
and lower levels of ICAM-1 in HIV+ men. Race was
significantly related to sTNFaR I and II. Increased body mass
index was also associated with higher IL-6, hs-CRP, D-dimer,
and fibrinogen levels in HIV men and lower levels of ICAM-1
in HIV+ men. Higher body mass index also had positive
correlations with levels of sTNFaR I and II in HIV men, while
these correlations were negative in HIV+ patients. Serum
cholesterol levels, use of hypertension medications, and
smoking pack-years were other CAD risk factors that were
correlated with some of the biomarkers, but in a less
consistent manner. Among HIV clinical factors, current CD4+
count is associated with higher levels of D-dimer, hs-CRP, and
sTNFaR II, and diagnosis of AIDS was related to greater levels
of sTNFaR I and II (data not presented).
As previously reported,46 HIV+ men had a higher preva-
lence of noncalcified plaques (62.8% versus 53.7%, respec-
tively, P=0.02) on CTA, and a greater extent of noncalcified
plaque (Wilcoxon Rank-Sum P-value for noncalcified plaque
score <0.01). There were no statistically significant differ-
ences between the 2 groups in the CAC score or in the
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Table 1. Characteristics of the Multicenter AIDS Cohort Study (MACS) Participants Undergoing Cardiac CT Scan*
HIV-Infected (N=575) HIV-Uninfected (N=348) P Value
Age, y 52.7 (6.6) 55.4 (7.2) <0.001
Race
White (%) 52.9 67.2 <0.001
African American (%) 34.1 24.4
Hispanic/other (%) 13.0 8.3
Hypertension (%) 49.0 43.7 0.13
Systolic blood pressure, mm Hg 126.6 (15.4) 127.9 (14.6) 0.22
Hypertension medications (%) 35.0 31.7 0.30
Diabetes (%) 14.8 10.5 0.08
Diabetes medications (%) 8.7 8.1 0.77
Tobacco use
Never smoker (%) 24.7 25.5 0.002
Current smoker (%) 31.5 21.2
Former smoker (%) 43.8 53.3
Smoking pack-years† 6.5 (0–24.0) 0.7 (0–20.1) 0.003†
Body mass index, kg/m2 26.0 (4.5) 27.4 (5.0) <0.001
Total cholesterol, mg/dL 186.6 (43.1) 192.5 (35.9) 0.03
LDL cholesterol, mg/dL 105.8 (36.1) 114.7 (31.7) <0.001
HDL cholesterol, mg/dL 48.6 (16.2) 53.7 (15.3) <0.001
Triglycerides, mg/dL 175.5 (202.0) 122.2 (66.2) <0.001
Lipid-lowering medications (%) 33.9 31.2 0.39
Serum creatinine, mg/dL 1.1 (0.5) 1.0 (0.2) 0.01
AHA/ACC 2013 risk score (%) 8.2 (4.5–12.4) 8.5 (4.5–12.5) 0.44†
AHA/ACC 2013 risk category 0.51
<5% risk (%) 30.4 26.3
5% to 7.4% risk (%) 15.9 18.6
≥7.5% (%) 53.7 55.1
HIV clinical factors
Current HIV RNA undetectable (<50 copies/mL) (%) 82.6
Current HIV RNA among detectable patients, copies/mL 842 (139–23 300)†
Current CD4+ T-cell count, cells/mm3 698 (499–936)†
CD4+ T-cell count nadir, cells/mm3 367 (242–557)†
HAART experienced (%) 96.0
Protease inhibitor use (%) 44.8
NNRTI use (%) 46.8
HAART duration, y 9.5 (6.3–12.5)†
Protease inhibitor duration, y 4.9 (0.3–9.6)†
NNRTI duration, y 4.0 (0.7–8.0)†
ACC indicates American College of Cardiology; AHA, American Heart Association; CT, computed tomography; HAART, highly active antiretroviral treatment; HDL, high-density lipoprotein
cholesterol; LDL, low-density lipoprotein cholesterol; NNRTI, non-nucleoside reverse transcriptase inhibitor.
*Mean (SD) is presented for continuous variables with normal distribution and percentage for categorical variables.
†Median (interquartile range) presented because the distribution was not normal. Wilcoxon Rank-Sum test was used for comparison between groups.
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prevalence of CAC, mixed or calcified plaques, or coronary
artery stenosis (Table 4).
Table 5 summarizes the associations of inflammatory
biomarkers with coronary artery stenosis on CTA studies. In
HIV+ men, higher levels of IL-6 and ICAM-1 were significantly
associated with greater prevalence of moderate to severe
(≥50%) coronary artery stenosis on CTA (in separate models),
and these associations remained significant even after
adjustment for traditional cardiovascular risk factors and
HIV clinical factors. Every SD increase in log-IL-6 and
log ICAM-1 was associated with 30% and 60%, respectively,
increase in prevalence of at least moderate coronary stenosis
(≥50%) among HIV+ men (P<0.05 for all), adjusting for other
risk factors. Similarly, higher levels of sTNFaR I and sTNFaR II
were associated with higher prevalence of severe (≥70%)
coronary artery stenosis. The prevalence ratios for severe
coronary artery stenosis for every SD increase in log sTNFaR I
and log sTNFaR II were 2.3 (95% CI: 1.3, 4.2; P=0.006) and
1.7 (95% CI: 1.1, 2.7; P=0.02), respectively, after adjustment
for traditional risk factors and HIV clinical factors. D-dimer
levels were also associated with coronary artery stenosis
greater than 50% in HIV men (adjusted prevalence ratio for
each SD increase in log D-dimer: 1.4, P=0.03). The relation-
ship between levels of inflammatory biomarkers and coronary
stenosis follows a relative dose–response pattern. Figure
illustrates the prevalence of moderate to severe (≥50%)
coronary artery stenosis in different quartiles of inflammatory
biomarkers in HIV+ individuals and all participants.
Higher serum levels of IL-6, sTNFaR I, and sTNFaR II were
also associated with a greater CAC score in HIV+ men (each
SD increase in the log of levels of each of these factors
associated with 0.3, 0.2, and 0.2 units, respectively, increase
in log-CAC score, all P≤0.01), and these associations
remained significant after adjustment for traditional risk
factors and HIV clinical factors. To provide a frame of
reference, 0.2 and 0.3 units increase in log-CAC score
Table 2. Distribution of Serum Inflammatory Markers Among the Multicenter AIDS Cohort Study (MACS) Participants Who Had
Cardiac CT Scan*
HIV Infected (N=575) HIV Uninfected (N=348) SD P Value
Interleukin-6, pg/mL 1.5 (1.0–2.5) 1.3 (0.9–2.1) 6.1 0.001†
ICAM-1, ng/mL 257.8 (214.7–315.0) 228.6 (193.1–273.5) 116.2 0.007†
Fibrinogen, mg/dL 326 (278–377) 332 (292–376) 92.7 0.63
D-dimer, lg/mL 0.17 (0.11–0.29) 0.20 (0.13–0.3) 0.8 0.43
CRP, mg/dL 1.24 (0.64–2.76) 0.95 (0.52–1.92) 4.2 <0.001†
sTNFaR I, pg/mL 1178 (973–1495) 1160 (953–1378) 1154 0.002†
sTNFaR II, pg/mL 6622 (5390–8285) 5844 (4961–6902) 3519 <0.001†
CPR indicates C-reactive protein; ICAM-1, intracellular adhesion molecule 1; sTNFaR, soluble-tumor necrosis.
*Inflammatory markers are presented as median (interquartile range). P values are calculated using t test after log transformation in all the markers except fibrinogen. SDs are provided to
facilitate interpretation of standardized variables.
†Statistically significant findings.
Table 3. Distribution of Serum Inflammatory Markers Among Virologically Suppressed HIV+ and HIV Men in the Multicenter
AIDS Cohort Study (MACS) Participants Who Had Cardiac CT Scan*
Virologically Suppressed†
HIV-Infected (N=475)
HIV Uninfected
(N=348) P Value
Interleukin 6, pg/mL 1.5 (1.0–2.3) 1.3 (0.9–2.1) 0.04‡
ICAM-1, ng/mL 252.4 (209.0–304.5) 228.6 (193.1–273.5) 0.06
Fibrinogen, mg/dL 322 (273–373) 332 (292–376) 0.40
D-dimer, lg/mL 0.17 (0.11–0.27) 0.20 (0.13–0.3) 0.34
CRP, mg/dL 1.23 (0.66–2.76) 0.95 (0.52–1.92) <0.001‡
sTNFaR I, pg/mL 1193 (988–1501) 1160 (953–1378) 0.002‡
sTNFaR II, pg/mL 6457 (5326–8054) 5844 (4961–6902) <0.001‡
CT indicates computed tomography; CRP, C-reactive protein; ICAM-1, intracellular adhesion molecule-1; sTNFaR I, soluble tumor necrosis factor a receptor I.
*Inflammatory markers are presented as median (interquartile range). P values are calculated using t test after log transformation in all the markers except fibrinogen.
†Defined as undetectable viral load.
‡Statistically significant findings.
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correspond to 22% and 35% increase in CAC score,
respectively. These 3 biomarkers were also associated with
presence of CAC in minimally adjusted models, although
serum IL-6 was the only biomarker that continued to be
marginally significant (PR: 1.1, P=0.06) after adjustment for
risk factors. The only inflammatory biomarker associated with
CAC score in HIV men was IL-6, which did not remain
significant in adjusted models (Table 6).
In general, the studied inflammatory biomarkers were not
significant determinants of plaque composition and extent on
CTA (presence and extent of any plaque, or of noncalcified,
calcified, or mixed plaque). For the purpose of brevity, all
these results are not presented; but some of these results are
summarized in Table 7 as examples. Fibrinogen level was the
only biomarker that was significantly associated with the
extent of noncalcified plaques in HIV+ men in minimally
adjusted models (PR for each point increase in plaque score:
1.1 [95% CI: 1.03, 1.2], P<0.01) and after further adjustment
for other covariates (PR for each point increase: 1.2 [95% CI:
1.02, 1.4], P=0.03).
The interaction terms between inflammatory biomarkers
and HIV serostatus were not statistically significant. As
mentioned above, the analyses were done in 923 participants
who did not have any missing values for the primary
biomarkers of interest. Repeating these analyses in the whole
study population after imputing missing values for biomarkers
and CAD risk factors (using multiple imputations) did not yield
significantly different results. Also, when the analyses were
limited to participants with undetectable viral load, the results
did not change significantly.
Discussion
To our knowledge, this is the largest study of the association
between inflammatory biomarkers and measures of subclinical
coronary artery disease using CTA in an HIV+ population. Our
results demonstrate that several inflammatory biomarkers
representing different domains of inflammation (IL-6, ICAM-1,
sTNFaR I, and sTNFaR II) were significantly associated with a
greater prevalence of coronary artery stenosis on CTA in HIV+
men, and these associations were independent of traditional
risk factors and HIV clinical factors. Our study also shows that
IL-6, sTNFaR I, and sTNFaR II were independently related to
extent of coronary artery calcification in HIV+ men. The study
expands our knowledge of the relationship between inflamma-
tory biomarkers and coronary plaque characteristics. Although
HIV-infected patients have higher prevalence of coronary artery
plaques on CTA, predominantly noncalcified plaques, the
Table 4. Coronary Artery CT Scan Findings of the Multicenter AIDS Cohort Study (MACS) Participants Who Had Cardiac CT Scan
HIV Infected* HIV Uninfected P Value**
Calcium score N=575 N=347
CAC present: Agatston Score >0 (%) 52.5 52.7 0.95
CAC score among those with calcium present 70 (21–184) 77 (23–248) 0.69†
CAC score >300 (%) 7.8 11.2 0.08
Coronary artery stenosis N=411 N=281
Prevalence of any coronary stenosis ≥50% (%) 15.1 14.6 0.86
Prevalence of any coronary stenosis ≥70% (%) 6.6 7.1 0.78
Total segment stenosis score 2 (1–6) 2 (1–5) 0.65‡
Coronary plaques N=411 N=281
Prevalence of any coronary plaque (%) 75.4 71.2 0.22
Prevalence of noncalcified plaque (%) 62.8 53.7 0.02§
Prevalence of mixed plaque (%) 33.4 33.0 0.91
Prevalence of calcified plaque (%) 33.4 40.3 0.06
Total Plaque Score 2 (1–5) 2 (1–5) 0.63‡
Noncalcified Plaque Score 1 (0–3) 1 (0–2) 0.004‡§
Mixed Plaque Score 0 (0–1) 0 (0–1) 0.66‡
Calcified Plaque Score 0 (0–1) 0 (0–2) 0.03‡§
CAC indicates coronary artery calcification; CT, computed tomography.
*Data are presented as median (interquartile range) for continuous variables and percentage for categorical variables. P values were calculated by v2 test for categorical variables, Student
t test with log transformation (†), or Wilcoxon Rank-Sum test (‡). Note that Wilcoxon Rank-Sum test is a nonparametric test that tests rank-sums, rather than medians. Therefore, medians
may be similar while there are significant differences in rank-sums. However, medians are provided in the table as a commonly used estimate for variables without normal distribution.
§Statistically significant findings.
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studied inflammatory biomarkers were not associated with
presence and extent of these coronary plaques and therefore do
not appear to be mediating these associations.
Previous studies on HIV+ populations have reported the
relationship of inflammatory biomarkers with cardiovascular
mortality,26 evidence of ischemia on ECGs,51 and traditional
risk factors for CAD.52 However, little is known about the
relationship of these biomarkers with subclinical measures of
atherosclerosis, specifically coronary artery stenosis and
plaque characterization on CT scan, in HIV+ patients. Previ-
ously, a study of 60 HIV+ and 30 HIV women reported higher
prevalence of noncalcified plaques in HIV+ women.53 Although
that study showed that sCD163 (a marker of monocyte
activation) was related to plaque characterization,53 there were
no significant differences in levels of IL-6 between HIV+ and
HIV women. Similarly, another study by the same group on
101 HIV+ and 41 HIV men showed increased plaque
vulnerability in HIV+ patients and the plaque vulnerability was
related to sCD163, but not to IL-6, hs-CRP, or D-dimer.54 Our
study expands our knowledge by providing detailed evaluation
of coronary atherosclerosis using CT scans and determining the
relationship of CT scan findings with general markers of
inflammation and coagulation (fibrinogen and D-dimer) in a
larger extensively phenotyped population.
Table 5. Associations of Inflammatory Markers With Coronary Artery Stenosis on Coronary CT Angiography*
HIV-Infected (N=411)† HIV-Uninfected (N=281)†
Model 1 Model 2 Model 3 Model 1 Model 2
Coronary stenosis ≥50%
Log-IL-6 1.3 (1.1–1.6), 0.003‡ 1.3 (1.04–1.6), 0.02‡ 1.3 (1.1–1.5), 0.01‡ 1.1 (0.8–1.5), 0.77 0.8 (0.5–1.3), 0.47
Log ICAM-1 1.6 (1.2–2.2), 0.001‡ 1.4 (1.03–1.9), 0.03‡ 1.5 (1.03–2.1), 0.035‡ 1.5 (0.99–2.4), 0.06 1.2 (0.8–1.8), 0.31
Fibrinogen 1.1 (0.9–1.3), 0.26 1.2 (0.9–1.6), 0.15 1.3 (0.95–1.7), 0.10 0.97 (0.6–1.6), 0.91 0.93 (0.7–1.3), 0.70
Log D-dimer 1.2 (0.9–1.5), 0.18 1.1 (0.9–1.5), 0.36 1.2 (0.9–1.6), 0.20 1.2 (0.9–1.8), 0.25 1.4 (1.03–2.0), 0.03‡
Log-CRP 1.2 (1.0–1.6), 0.07 1.2 (0.9–1.5), 0.15 1.3 (1.0–1.6), 0.06 1.0 (0.7–1.4), 0.99 0.8 (0.6–1.1), 0.23
Log sTNFaR I 1.2 (0.9–1.6), 0.23 1.1 (0.8–1.4), 0.55 1.1 (0.8–1.5), 0.58 0.8 (0.6–1.1), 0.20 0.6 (0.4–0.8), 0.004‡
Log sTNFaR II 1.3 (1.1–1.6), 0.007‡ 1.2 (0.9–1.4), 0.17 1.2 (0.97–1.6), 0.09 0.9 (0.6–1.4), 0.58 0.7 (0.4–1.2), 0.22
Coronary stenosis ≥70%
Log-IL-6 1.3 (1.0–1.8), 0.05‡ 1.1 (0.8–1.5), 0.48 1.0 (0.7–1.5), 0.83 0.98 (0.5–1.8), 0.95 0.7 (0.3–1.8), 0.48
Log ICAM-1 1.4 (0.97–2.0), 0.07 1.1 (0.8–1.5), 0.56 1.0 (0.7–1.5), 0.83 1.9 (0.9–3.7), 0.07 1.5 (0.8–2.8), 0.22
Fibrinogen 1.1 (0.8–1.4), 0.64 1.0 (0.6–1.7), 0.97 1.0 (0.6–1.8), 0.90 1.2 (0.6–2.5), 0.66 1.2 (0.8–2.0), 0.43
Log D-dimer 1.1 (0.7–1.6), 0.69 1.1 (0.7–1.7), 0.79 1.1 (0.7–1.7), 0.71 1.2 (0.7–2.0), 0.54 1.4 (0.9–2.1), 0.14
Log-CRP 1.2 (0.8–1.8), 0.27 1.2 (0.8–1.9), 0.39 1.3 (0.8–2.0), 0.25 1.3 (0.8–2.1), 0.30 1.3 (0.8–2.1), 0.22
Log sTNFaR I 1.9 (1.2–3.0), 0.004‡ 1.9 (1.2–3.0), 0.004‡ 2.3 (1.3–4.2), 0.006‡ 0.9 (0.6–1.4), 0.67 0.7 (0.5–1.04), 0.08
Log sTNFaR II 1.6 (1.2–2.1), 0.001‡ 1.4 (1.0–2.0), 0.06 1.7 (1.1–2.7), 0.02‡ 1.2 (0.6–2.3), 0.65 1.1 (0.5–2.3), 0.86
Model 1: minimally adjusted models (including age, race/ethnicity, study center, and study cohort [pre- vs post-2001]). Model 2: Model 1 plus traditional cardiovascular risk factors
(systolic blood pressure, antihypertensive medication use, diabetes medication use, fasting glucose, total cholesterol, HDL cholesterol, use of lipid-lowering medications, body mass index,
smoking, and pack-years of smoking). Model 3: Model 2 plus parameters of HIV infection (HIV duration, current viral load, current and nadir CD4+ T-cell counts, and history of an AIDS-
defining malignancy or opportunistic infection, and duration of ART use). ART indicates antiretroviral therapy; CAD, coronary artery disease; CRP, C-reactive protein; CT, computed
tomography; HDL, high-density lipoprotein cholesterol; ICAM-1, intracellular adhesion molecule-1; IL-6, interleukin-6; sTNFaR I, soluble tumor necrosis factor a receptor I.
*Results presented as prevalence ratio (95% CI), P value.
†N for these analyses was 692 participants who had CT scan and had no missing values for any of the 7 inflammatory markers of interest. The number of participants dropped in Models 2
and 3 due to missing values in CAD risk factors and clinical parameters of HIV infection was negligible (less than 3%).
‡Statistically significant findings.
Figure. Prevalence of coronary artery stenosis (≥50%) on CT scan
with quartiles of inflammatory markers in HIV-infected men and all
participants in the MACS study. CT indicates computed tomogra-
phy; IL-6, interleukin-6; MACS, Multicenter AIDS Cohort Study;
TNFaR II, tumor necrosis factor a receptor II.
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Our results showed that HIV+ participants, even those with
undetectable viremia, had higher levels of inflammatory mark-
ers. More importantly, while these markers were not strong
predictors of presence, extent, and composition of coronary
plaques seen on CTA, they were independently associated with
coronary artery stenosis. This is important as coronary artery
stenosis could be considered the closest indicator of potentially
clinically significant CAD among the measured CT scan
parameters, and is the main parameter that is used in clinical
practice for decision making with regard to referral for more
invasive evaluations, particularly if associated with symptoms.
In other words, these markers are not associated with the early
stages of atherosclerosis, but are related to a more advanced
stage, namely, coronary artery stenosis. These findings are
consistent with the results of our previous analyses on the
relationship of adiponectin and circulatorymarkers ofmonocyte
activation with CT scan findings in the MACS population.44,55
The biomarkers of inflammation and coagulation included
in this study are widely used to represent different domains of
inflammation (systemic mediators, endothelial cell activation,
TNF-a-mediated immune cell activation, and acute phase
response proteins) and coagulation, and the generally positive
associations suggest widespread involvement of many facets
of inflammation in HIV-mediated atherosclerosis. Some of
these markers are widely available for clinical use, and have
been suggested by other studies to be related to clinical CAD
in the general population.30,31 In the SMART study,56 elevated
IL-6, hs-CRP, and D-dimer levels were related to risk for future
CVD events in HIV+ patients, although the relationships with
all-cause mortality were stronger than for CVD. More recently,
Nordell et al57 analyzed 3 trials, including the SMART trial,
and reported that IL-6 and D-dimer, but not CRP, are
associated with future fatal CVD and mortality following a
nonfatal cardiovascular event. These studies have focused on
prediction of future clinical events based on baseline levels of
biomarkers. Our study enhances our knowledge by showing
that the associations reported in these studies can be
expanded to subclinical coronary artery stenosis determined
by CTA, but not to the extent and composition of the
atherosclerotic plaques. Interestingly, after adjustment for
Table 6. Associations of Inflammatory Markers With Coronary Artery Calcification on Cardiac CT Scan*
HIV Seropositive (N=575)† HIV Seronegative (N=347)†
Model 1 Model 2 Model 3 Model 1 Model 2
CAC score (Log)‡
Log-IL-6 0.3 (0.1–0.5), <0.01§ 0.2 (0.03–0.4), 0.02§ 0.2 (0.03–0.4), 0.03§ 0.3 (0.02–0.6), 0.04§ 0.1 (0.2 to 0.4), 0.50
Log ICAM-1 0.1 (0.0–0.3), 0.06 0.1 (0.05 to 0.3), 0.19 0.1 (0.1 to 0.2), 0.33 0.1 (0.3 to 0.5), 0.56 0.1 (0.3 to 0.4), 0.68
Fibrinogen 0.1 (0.1 to 0.2), 0.53 0.1 (0.04 to 0.3), 0.14 0.1 (0.0 to 0.4), 0.08 0.2 (0.2 to 0.5), 0.45 0.03 (0.4 to 0.4), 0.89
Log D-dimer 0.1 (0.1 to 0.3), 0.27 0.1 (0.1 to 0.3), 0.28 0.1 (0.1 to 0.3), 0.33 0.1 (0.1 to 0.3), 0.33 0.1 (0.1 to 0.3), 0.38
Log-CRP 1.30.1 (0.1 to 0.3), 0.17 0.1 (0.1 to 0.2), 0.55 0.1 (0.1 to 0.3), 0.37 0.0 (0.2 to 0.3), 0.80 0.2 (0.5 to 0.1), 0.28
Log sTNFaR I 0.2 (0.1–0.4), <0.01§ 0.2 (0.0–0.4), 0.05§ 0.2 (0.0–0.4), 0.047§ 0.0 (0.3 to 0.2), 0.86 0.2 (0.5 to 0.1), 0.12
Log sTNFaR II 0.2 (0.04–0.4), 0.01§ 0.2 (0.0–0.4), 0.05§ 0.2 (0.0–0.4), 0.046§ 0.1 (0.2 to 0.5), 0.46 0.0 (0.3 to 0.4), 0.82
Presence of CAC
Log-IL-6 1.1 (1.03–1.2), 0.006§ 1.1 (1.0–1.15), 0.06§ 1.1 (1.0–1.2), 0.06§ 1.1 (0.98–1.2), 012 1.0 (0.9–1.2), 0.63
Log ICAM-1 1.1 (0.97–1.1), 0.21 1.1 (0.96–1.2), 0.25 1.0 (0.95–1.1), 0.37 1.1 (0.9–1.3), 0.45 1.0 (0.9–1.2), 0.54
Fibrinogen 1.0 (0.96–1.1), 0.65 1.0 (0.97–1.1), 0.39 1.0 (0.9–1.1), 0.14 1.03 (0.9–1.2), 0.88 1.0 (0.86–1.1), 0.86
Log D-dimer 1.0 (0.95–1.1), 0.46 1.0 (0.9–1.1), 0.71 1.0 (0.9–1.1), 0.99 1.0 (0.9–1.1), 0.53 1.0 (0.9–1.1), 0.50
Log-CRP 1.0 (0.97–1.1), 0.27 1.0 (0.93–1.1), 0.86 1.0 (0.9–1.1), 0.72 1.0 (0.9–1.1), 0.61 0.99 (0.9–1.1), 0.82
Log sTNFaR I 1.1 (1.02–1.1), 0.01§ 1.0 (0.96–1.1), 0.40 1.0 (0.96–1.1), 0.39 0.99 (0.9–1.1), 0.89 0.98 (0.9–1.1), 0.67
Log sTNFaR II 1.1 (1.0–1.1), 0.04§ 1.0 (0.97–1.1), 0.27 1.0 (0.96–1.1), 0.32 1.0 (0.9–1.2), 0.65 1.0 (0.9–1.2), 0.81
Model 1: minimally adjusted models (including age, race/ethnicity, study center, and study cohort [pre- vs post-2001]). Model 2: Model 1 plus traditional cardiovascular risk factors
(systolic blood pressure, antihypertensive medication use, diabetes medication use, fasting glucose, total cholesterol, HDL cholesterol, use of lipid-lowering medications, body mass index,
smoking, and pack-years of smoking). Model 3: Model 2 plus parameters of HIV infection (HIV duration, current viral load, current and nadir CD4+ T-cell counts, and history of an AIDS-
defining malignancy or opportunistic infection, and duration of ART use). ART indicates antiretroviral therapy; CAC, coronary artery calcification; CAD, coronary artery disease; CRP, C-
reactive protein; CT, computed tomography; HDL, high-density lipoprotein cholesterol; ICAM-1, intracellular adhesion molecule-1; IL-6, interleukin-6; sTNFaR I, soluble tumor necrosis
factor a receptor I.
*Results presented as (prevalence ratio [95% CI], P value) for presence of CAC score and (regression coefficient [95% CI], P value) for log-CAC score. These values correspond to 1 SD
increase in the value of biomarkers.
†N for these analyses was 922 participants who had CT scan and had no missing values for any of the 7 inflammatory markers of interest. The number of participants dropped in Models 2
and 3 due to missing values in CAD risk factors and clinical parameters of HIV infection was negligible (less than 3%).
‡In order to include participants with CAC score of 0, log of CAC score was calculated after adding a 1 to the scores. Therefore, the independent variable in this model is log (CAC score+1).
§Statistically significant findings.
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Table 7. Associations of Inflammatory Markers With Plaque Characterization on Coronary CT Angiography*
HIV-Infected (N=422)† HIV-Uninfected (N=285)†
Model 1 Model 2 Model 3 Model 1 Model 2
Presence of any plaque
Log-IL-6 1.0 (0.99–1.1), 0.17 1.0 (0.97–1.1), 0.38 1.0 (0.97–1.1), 0.39 1.0 (0.96–1.1), 0.36 1.0 (0.93–1.1), 0.87
Log ICAM-1 1.0 (0.97–1.1), 0.62 1.0 (0.96–1.1), 0.85 1.0 (0.96–1.1), 0.99 1.0 (0.9–1.2), 0.46 1.1 (0.9–1.2), 0.43
Fibrinogen 1.0 (0.99–1.1), 0.10 1.0 (0.97–1.1), 0.37 1.0 (0.98–1.1), 0.23 1.0 (0.9–1.1), 0.90 1.0 (0.9–1.1), 0.51
Log D-dimer 1.0 (0.9–1.04), 0.72 1.0 (0.9–1.03), 0.60 1.0 (0.9–1.04), 0.66 1.0 (0.9–1.1), 0.97 1.0 (0.9–1.1), 0.78
Log-CRP 1.0 (0.97–1.1), 0.54 1.0 (0.95–1.1), 0.89 1.0 (0.95–1.1), 0.82 1.0 (0.96–1.1), 0.37 1.0 (0.96–1.1), 0.34
Log sTNFaR I 1.0 (0.9–1.1), 0.86 1.0 (0.9–1.1), 0.64 1.0 (0.9–1.05), 0.58 0.97 (0.9–1.0), 0.37 0.98 (0.9–1.1), 0.64
Log sTNFaR II 1.0 (0.95–1.0), 0.98 0.99 (0.9–1.1), 0.81 1.0 (0.9–1.05), 0.62 0.95 (0.9–1.1), 0.34 0.96 (0.9–1.1), 0.49
Calcified Plaque Score‡
Log-IL-6 1.1 (0.97–1.3), 0.12 1.1 (0.9–1.4), 0.40 1.1 (0.9–1.4), 0.23 1.1 (0.9–1.4), 0.31 1.0 (0.8–1.3), 0.77
Log ICAM-1 1.1 (0.9–1.4), 0.30 1.1 (0.9–1.4), 0.29 1.1 (0.9–1.3), 0.33 0.9 (0.7–1.2), 0.45 0.9 (0.6–1.2), 0.34
Fibrinogen 0.97 (0.8–1.1), 0.70 1.0 (0.8–1.3), 0.81 1.1 (0.8–1.4), 0.52 0.97 (0.7–1.3), 0.81 0.9 (0.7–1.3), 0.60
Log D-dimer 0.9 (0.7–1.1), 0.44 0.9 (0.7–1.2), 0.58 1.0 (0.8–1.3), 0.99 1.1 (0.8–1.4), 0.25 1.2 (0.96–1.4), 0.13
Log-CRP 0.96 (0.8–1.2), 0.67 0.97 (0.8–1.2), 0.80 0.99 (0.8–1.2), 0.98 0.9 (0.7–1.1), 0.16 0.8 (0.6–1.0), 0.04§
Log sTNFaR I 1.0 (0.7–1.4), 0.99 0.9 (0.7–1.1), 0.30 0.8 (0.7–1.1), 0.17 0.96 (0.8–1.2), 0.72 0.9 (0.7–1.1), 0.17
Log sTNFaR II 1.1 (0.9–1.3), 0.21 1.2 (0.96–1.4), 0.11 1.2 (1.0–1.5), 0.05§ 1.0 (0.8–1.3), 0.83 1.0 (0.7–1.4), 0.99
Noncalcified Plaque Score‡
Log-IL-6 1.1 (0.98–1.3), 0.10 1.1 (0.9–1.2), 0.19 1.1 (0.95–1.2), 0.24 1.1 (0.96–1.3), 0.18 0.95 (0.8–1.1), 0.52
Log ICAM-1 0.99 (0.9–1.1), 0.82 0.97 (0.9–1.1), 0.48 0.97 (0.9–1.1), 0.56 1.1 (0.9–1.3), 0.31 1.0 (0.9–1.3), 0.46
Fibrinogen 1.1 (1.03–1.2), <0.01§ 1.2 (1.03–1.5), 0.02§ 1.2 (1.02–1.4), 0.03§ 1.1 (0.8–1.5), 0.70 1.1 (0.8–1.4), 0.72
Log D-dimer 1.0 (0.9–1.1), 0.87 1.0 (0.9–1.1), 0.74 1.0 (0.8–1.1), 0.65 1.1 (0.9–1.3), 0.46 1.1 (0.9–1.3), 0.33
Log-CRP 1.1 (0.9–1.2), 0.28 1.0 (0.9–1.2), 0.76 1.0 (0.9–1.2), 0.59 1.2 (1.02–1.5), 0.03§ 1.1 (0.9–1.4), 0.32
Log sTNFaR I 1.1 (0.9–1.3), 0.17 1.1 (0.9–1.3), 0.29 1.1 (0.9–1.3), 0.17 1.0 (0.9–1.2), 0.65 1.0 (0.8–1.2), 0.97
Log sTNFaR II 1.0 (0.9–1.2), 0.79 1.0 (0.8–1.1), 0.66 1.0 (0.9–1.1), 0.94 1.0 (0.8–1.3), 0.90 0.95 (0.7–1.3), 0.73
Mixed Plaque Score‡
Log-IL-6 1.1 (0.9–1.4), 0.21 1.1 (0.85–1.3), 0.61 1.0 (0.8–1.3), 0.89 1.0 (0.8–1.4), 0.79 0.8 (0.5–1.2), 0.32
Log ICAM-1 1.2 (0.9–1.4), 0.20 1.1 (0.9–1.3), 0.31 1.1 (0.9–1.3), 0.45 1.2 (0.9–1.6), 0.26 1.0 (0.8–1.3), 0.83
Fibrinogen 1.0 (0.9–1.2), 0.72 1.1 (0.8–1.4), 0.64 1.1 (0.8–1.4), 0.62 1.4 (0.9–2.1), 0.11 1.2 (0.9–1.7), 0.17
Log D-dimer 0.9 (0.7–1.1), 0.27 0.9 (0.7–1.1), 0.16 0.9 (0.7–1.1), 0.18 0.9 (0.7–1.2), 0.43 0.8 (0.6–1.1), 0.17
Log-CRP 1.0 (0.9–1.3), 0.62 1.0 (0.8–1.3), 0.84 1.0 (0.8–1.2), 0.92 1.0 (0.8–1.3), 0.92 0.8 (0.7–1.1), 0.14
Log sTNFaR I 1.2 (1.0–1.5), 0.035§ 1.1 (0.9–1.4), 0.22 1.1 (0.9–1.3), 0.36 1.0 (0.8–1.3), 0.94 0.8 (0.5–1.1), 0.15
Log sTNFaR II 1.1 (0.8–1.3), 0.60 0.97 (0.7–1.3), 0.85 0.9 (0.7–1.1), 0.36 1.1 (0.8–1.5), 0.56 0.9 (0.6–1.3), 0.55
Total Plaque Score‡
Log-IL-6 1.1 (1.02–1.2), 0.02§ 1.1 (0.98–1.2), 0.12 1.1 (0.98–1.2), 0.14 1.1 (0.97–1.3), 0.15 0.95 (0.8–1.1), 0.52
Log ICAM-1 1.0 (0.96–1.1), 0.27 1.0 (0.96–1.1), 0.48 1.0 (0.9–1.1), 0.65 1.1 (0.9–1.2), 0.44 1.0 (0.8–1.2), 0.85
Fibrinogen 1.1 (0.98–1.2), 0.13 1.1 (0.99–1.3), 0.08 1.1 (0.99–1.3), 0.07 1.1 (0.9–1.4), 0.23 1.1 (0.9–1.3), 0.31
Log D-dimer 0.96 (0.9–1.1), 0.37 0.9 (0.8–1.04), 0.23 0.9 (0.8–1.1), 030 1.0 (0.9–1.2), 0.54 1.1 (0.9–1.2), 0.43
Log-CRP 1.0 (0.9–1.1), 0.59 1.0 (0.9–1.1), 0.99 1.0 (0.9–1.1), 0.81 1.1 (0.9–1.2), 0.45 0.9 (0.8–1.03), 0.17
Log sTNFaR I 1.1 (0.98–1.3), 0.10 1.03 (0.9–1.2), 0.50 1.03 (0.9–1.2), 0.60 1.0 (0.9–1.1), 0.90 0.9 (0.8–1.02), 0.09
Log sTNFaR II 1.1 (0.95–1.2), 0.32 1.0 (0.9–1.1), 0.83 1.1 (0.9–1.1), 0.80 1.05 (0.9–1.2), 0.56 0.95 (0.8–1.1), 0.60
Model 1: Minimally adjusted models (including age, race/ethnicity, study center, and study cohort [pre- vs post-2001]). Model 2: Model 1 plus traditional cardiovascular risk factors
(systolic blood pressure, antihypertensive medication use, diabetes medication use, fasting glucose, total cholesterol, HDL cholesterol, use of lipid-lowering medications, body mass index,
smoking, and pack-years of smoking). Model 3: Model 2 plus parameters of HIV infection (HIV duration, current viral load, current and nadir CD4+ T-cell counts, and history of an AIDS-
defining malignancy or opportunistic infection, and duration of ART use). ART indicates antiretroviral therapy; CAD, coronary artery disease; CRP, C-reactive protein; CT, computed
tomography; HDL, high-density lipoprotein cholesterol; ICAM-1, intracellular adhesion molecule-1; IL-6, interleukin-6; sTNFaR I, soluble tumor necrosis factor a receptor I.
*Results presented as prevalence ratio (95% CI), P value.
†The number participants dropped in Models 2 and 3 due to missing values in CAD risk factors and clinical parameters of HIV infection was negligible (less than 3%).
‡The results for plaque scores are based on the Poisson regressions and represent prevalence ratio associated with 1 score increase in plaque scores.
§Statistically significant findings.
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HIV and CVD-related risk factors, the prevalence ratios of
coronary artery stenosis above 50% associated with each SD
increase in values of IL-6, hs-CRP, and D-dimer in our study
were comparable to the hazard ratios reported in the SMART
trial,56 although the association of hs-CRP with coronary
artery stenosis was only marginally significant (P=0.06) and
the relationship of D-dimer with coronary artery stenosis was
not statistically significant.
The stronger relationship of the studied inflammatory
markers with clinically important findings on CT scan
(coronary stenosis and CAC score rather than extent and
composition of atherosclerotic plaques) implies the potential
of these markers in clinical practice for risk stratification of
HIV-infected patients and possibly monitoring progression of
the subclinical atherosclerosis in this population. In other
words, combining our results with the results of the previous
studies on clinical CVD, it is possible that certain inflamma-
tory markers may indicate an increased likelihood that the
atherosclerotic process has progressed to subclinical stenosis
of the coronary arteries and might impose an increased risk of
CVD events in the future. However, further studies will be
needed to determine the accuracy and reliability of using
these markers in clinical practice.
The results of our study provide additional evidence of the
complexity of the immunologic and inflammatory changes in
HIV infection and their interactions with the atherosclerotic
process. While some of the analyzed markers (IL-6 and ICAM-1)
were independently associated with higher prevalence of
coronary artery stenosis of above 50%, some others (sTNFaR I
and sTNFaR II) were related to higher prevalence of more
severe (≥70%) coronary artery stenosis; and hs-CRP, D-dimer,
and fibrinogen did not have significant associations with
coronary stenosis. Also, some markers (IL-6, sTNFaR I, and
sTNFaR II) were associated with CAC score, while fibrinogen
was the only marker associated with the extent of noncalci-
fied plaques. While one should recognize the different
biological domains they represent when considering these
differences, all blood biomarkers have substantial indepen-
dent within-subject variability, along with analytical impreci-
sion, which also may explain some of the differences in
association with outcomes we have observed.
While in our study several inflammatory markers were
associated with coronary artery stenosis, these associations
were not significant in HIV participants. While the smaller
sample size in this group, coupled with the lower level of
inflammatory markers may play a role, this finding is
consistent with observations in the general population, viz,
that inflammation biomarkers are generally less strongly
related to measures of underlying atherosclerosis than they
are with clinical events58 and associate with clinical events
somewhat independently of measures of atherosclerosis.59
The relatively wider ranges of CIs for PRs in the HIV group
indicate the possibility of not being able to capture the
associations in this group due to power limitations. However,
as mentioned above, our sample size is larger than other
similar studies. Of note, the fact that the HIV control group
in MACS is drawn from the same reference population,
namely, men who have sex with men with similar risk of
smoking, drug use, and socioeconomic status, would minimize
the potential for unmeasured confounding and selection bias.
One of the major strengths of our study is that it benefits
from detailed phenotyping of subclinical CAD, using CTA in
addition to noncontrast CT scans in a large, well-defined cohort.
The large sample size of our study confirms that the lack of
association with some inflammatory markers and cardiac CT
scan findings in HIV+ men are less likely to be due to lack of
power. Our study, nonetheless, has some limitations. The cross-
section design of the study limits our ability to relate the
inflammatory markers measured at a certain point to the
atherosclerotic process that is developed over years. Long-term
follow-up of the participants of this study will help us better
understand the prognostic value of coronary CT scan findings,
such as CAC, noncalcified plaque, and coronary stenosis in
individuals with chronic inflammation due to HIV infection or
other chronic diseases—an area that is less studied. The
unstable nature of some of these inflammatory biomarkers, the
within-person variability (biological and lab-related), and the
fact that these markers represent global (rather than organ-
specific) inflammatory processes make it more challenging to
demonstrate mechanisms linking inflammatory biomarkers
with subclinical CAD. Additionally, while providing a compre-
hensive report of the relationship of seven biomarkers with
several measures of subclinical CAD on CT scan is one of the
strengths of this study, the large number of analyses performed
may also be a limitation of the study, as there is a possibility of
false-positive findings. Therefore, the emphasis has been put on
highlighting the associations that appear more consistent and
plausible. These analyses include several models with the same
predictors and outcomes, and the markers are correlated with
each other. Therefore, borderline results should be considered
cautiously. The fact that the P values associated with many
positive findings are highly significant is reassuring. Finally, our
study had less power to study the relationship of inflammatory
markers with CT scan findings in HIV men, and no definite
conclusions can be made about associations in women.
In conclusion, inflammatory biomarker levels, representing
several different aspects of inflammation, are higher in HIV+
men than HIV men and elevated levels of some of these
markers are associated with greater prevalence of coronary
artery stenosis, especially in HIV+ men. While inflammatory
biomarkers are significant indicators of clinically important
stenosis (≥50%) and CAC score, these markers are not
significantly related to the extent and composition of
atherosclerotic plaques. Our findings support the view that
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HIV-mediated inflammation is an important contributor to
CAD, and reflects the complexity of inflammatory processes in
HIV-infected individuals. Our ongoing studies will evaluate the
longitudinal relationship of these biomarkers with progression
of coronary artery atherosclerosis. Additional studies are
needed to continue to evaluate the potential for using these
markers for risk stratification and monitoring of high-risk
patients as well as the efficacy of therapeutic interventions.
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